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ABSTRACT
Objective: To evaluate the effectiveness and cost of
the pan-London pharmacy initiative, a programme that
allows administration of seasonal influenza vaccination
to eligible patients at pharmacies.
Design: We analysed 2013–2015 data on vaccination
uptake in pharmacies via the Sonar reporting system,
and the total vaccination uptake via 2011–2015
ImmForm general practitioner (GP) reporting system
data. We conducted an online survey of London
pharmacists who participate in the programme to
assess time use data, vaccine choice, investment costs
and opinions about the programme. We conducted an
online survey of London GPs to assess vaccine choice
of vaccine and opinions about the pharmacy vaccine
delivery programme.
Setting: All London boroughs.
Participants: London-based GPs, and pharmacies
that currently offer seasonal flu vaccination.
Interventions: Not applicable.
Main outcome measures: Comparison of annual
vaccine uptake in London across risk groups from
years before pharmacy vaccination introduction to after
pharmacy vaccination introduction. Completeness of
vaccine uptake reporting data. Cost to the National
Health Service (NHS) of flu vaccine delivery at
pharmacies with that at GPs. Cost to pharmacists of flu
delivery. Opinions of pharmacists and GPs regarding
the flu vaccine pharmacy initiative.
Results: No significant change in the uptake of
seasonal vaccination in any of the risk groups as a
result of the pharmacy initiative. While on average a
pharmacy-administered flu vaccine dose costs the NHS
up to £2.35 less than a dose administered at a GP, a
comparison of the 2 recording systems suggests there
is substantial loss of data.
Conclusions: Flu vaccine delivery through pharmacies
shows potential for improving convenience for vaccine
recipients. However, there is no evidence that
vaccination uptake increases and the use of 2 separate
recording systems leads to time-consuming data entry
and missing vaccine record data.
INTRODUCTION
The UK seasonal inﬂuenza (ﬂu) immunisa-
tion programme aims to protect those who
are most at risk of serious illness or death
from ﬂu infection and to reduce transmis-
sion of the infection, which contributes to
the protection of vulnerable patients in
whom vaccine efﬁcacy is low.1 Available
between September and January each year,
the National Health Service (NHS) currently
offers ﬂu vaccination free of charge to: (1)
anyone aged 65 years or older; (2) pregnant
women at any stage of pregnancy; (3) long-
stay care home residents; (4) those who are
in receipt of a carer’s allowance or those who
are the main carer for an elderly or disabled
person whose welfare may be at risk if they
fall ill; (5) patients with chronic disease:
chronic respiratory disease, chronic heart
disease, chronic kidney disease, chronic liver
disease, chronic neurological disease, dia-
betes, immunosuppression, and asplenia or
dysfunction of the spleen; and (6) all other
children aged 2, 3 and 4.2 The ﬁrst ﬁve
groups are offered inactivated vaccine,
whereas children with no clinical risks are
offered live attenuated vaccine. Until the
2013/2014 ﬂu season, general practitioners
(GPs) or nurses vaccinated all eligible indivi-
duals in London except in three administra-
tion areas where there were small pilot
studies for pharmacy delivery.
Strengths and limitations of this study
▪ London-based pharmacy initiative is the largest
evidence base on which to evaluate the potential
of the national pharmacy flu vaccine provision
programme roll out.
▪ No previous analysis of London-based pilot prior
to national programme roll out.
▪ First analysis to provide effectiveness and eco-
nomic evaluation across London-based pilot to
inform national programme implementation.
▪ Results may not be generalisable to other areas
of the country or the national pharmacy delivery
programme.
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To increase access and improve patient healthcare
choice and opportunity, particularly within underserved
communities, NHS England (London Region; NHS LR),
via consultation with North East London Local
Pharmaceutical Committee and Pharmacy London,
began the ‘pharmacy initiative’ in 2013/2014, which
enabled pharmacists to provide the seasonal ﬂu vaccine
to eligible individuals. Through this initiative, the NHS
reimbursed pharmacies when they vaccinated an individ-
ual aged 13 years or older with inactivated ﬂu vaccine
belonging to any of the ﬁrst ﬁve eligibility groups. From
2014/2015, the initiative was expanded to allow pharma-
cies to offer inactivated ﬂu vaccines to clinically at risk
children from aged 2 and older.
Community pharmacies offer vaccinations to both chil-
dren and adults in a number of countries, including the
USA3 and Canada.4 5 A London-wide patient survey pre-
viously conducted by the NHS recorded a high level of
patient satisfaction with the pharmacy initiative, with
patients reporting that convenience played a critical role
in their decision to get vaccinated at the pharmacy (see
online supplementary information A).
NHS England recently announced that pharmacies
nationwide would be able to offer ﬂu vaccines to eligible
patients for 2015/2016 ﬂu season.6 7 Thus, the
London-based initiative has been the largest of its kind
in England and, as such, can inform decisions about the
current national roll out. In particular, to broaden the
current pharmacy initiative to the rest of the country,
the London pilot programme must demonstrate effect-
iveness and cost-effectiveness relative to the previous
status quo of GP-only ﬂu vaccine administration.
In this study, we evaluate the impact of expanding ﬂu
vaccine provision into community pharmacies within ﬁve
key areas: (1) the impact on vaccination uptake; (2)
impact on the reporting system, data collection and
administrative burden; (3) pharmacy and GP opinions
on the pharmacy initiative; (4) the impact on individual
accessibility to ﬂu vaccine services; and (5) the cost of
ﬂu vaccine administration. These results can directly
inform the proposed nationwide programme by predict-
ing outcomes and raising likely issues.
METHODS
Data: Sonar and ImmForm data
To evaluate the uptake in pharmacies across London, we
used data from Sonar, a pharmacy-reporting system
detailing seasonal inﬂuenza vaccine administration by all
participating pharmacies, from 2013/2014 and 2014/
2015. Sonar data from 2014/2015 did not include strati-
ﬁcation by risk group. Individuals classiﬁed in Sonar
2013/2014 as ‘frontline healthcare staff’ (7% of the
68 220 patients reported as attending a pharmacy for
the ﬂu vaccine), ‘householders of immunocompromised
individuals’ (<1% of pharmacy patients) or ‘living in
long-stay accommodation facilities’ (<1% of pharmacy
patients) were not provided in the ImmForm, the
analogous database used for vaccine reporting by GPs,
and thus were excluded from the analysis. For each
vaccine recipient or set of recipients, Sonar data records
report the primary care trust (PCT) of the pharmacy
where the vaccine was administered, and the PCT of the
GP where the recipient is registered.
We used data on vaccine delivery reported by GP prac-
tices via the ImmForm system from 2010/2011 to 2014/
2015, provided by NHS LR. Pharmacies are required to
report any vaccine administration to the GP where their
patient is registered (this information is provided by the
patient). The GP practice is then required to enter this
information into the ImmForm system. For 2014/2015,
ImmForm data tally the vaccine doses administered
outside the GP practice. Prior to the 2013/2014 season,
ImmForm data stratiﬁed GP practice by PCT. In 2013/
2014, when administrative areas were reclassiﬁed from
PCTs to clinical commissioning groups (CCGs), the
ImmForm data reﬂected this change. For ease of com-
parison, we present the data across areas by PCTs where
applicable. All named areas were mapped identically
from PCT to CCG with the following exceptions: West
London (Kensington and Chelsea and QPP) CCG was
mapped to Kensington and Chelsea PCT; Central
London (Westminster) CCG was mapped to Westminster
PCT; Merton CCG and Sutton CCG were combined to
map to Sutton and Merton PCT; Richmond CCG was
mapped to Richmond and Twickenham PCT. ImmForm
data were stratiﬁed by inclusion criteria: (1) 65+ years,
(2) carers <65 years, (3) pregnant women with no clin-
ical risk factors, and (4) clinical (<65 years with diabetes,
kidney disease, heart disease, immunosuppression,
respiratory disease, neurological disease, liver disease.
Data: pharmacy survey
We analysed results of a survey conducted by NHS LR
involving 1230 pharmacies, which participated in the
pharmacy initiative, between 5 and 16 March 2015
across London (see online supplementary information
B; 5% (58) response rate). Data were collected on (1)
pharmacy staff time use for ﬂu vaccine procurement,
administration and paperwork; (2) ﬂu vaccine brand
choice; and (3) opinions about the pharmacy initiative.
Data were cleaned to remove any reported duration
ﬁgures that were over 3 SDs away from the mean or were
clearly typographical errors because they were non-
numeric or an order of magnitude greater than the
other responses.
Data: GP survey
We analysed results of a survey conducted by NHS LR to
all 1406 GP practices between 5 and 16 March 2015
across London (see online supplementary information
C; 24% (344) response rate). Data were collected on (1)
opinions about the pharmacy programme, (2) logistics
of vaccine delivery, (3) vaccine brand choice. Data were
cleaned to remove any responses that were unclear.
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Evaluating vaccine coverage and vaccine administration
reporting
As there were only a very small proportion of individuals
receiving their ﬂu vaccine at a pharmacy who might
have not been registered at a GP (<1%), we used the
total registered individuals from the GP ImmForm data
as the denominator in our calculations where
appropriate.
GP ImmForm data were stratiﬁed by ages 16 to under
65 years, whereas Sonar data were stratiﬁed by ages 13 to
under 65. Therefore, the total numbers eligible to
receive the vaccine at a pharmacy marginally inﬂated as
they included teenagers between 13 and 15 years.
However, as the number of people eligible to receive the
vaccine in this age bracket is likely extremely small, this
effect would also be very small.
To evaluate whether the extent to which vaccine
uptake in pharmacies is associated with high overall
vaccine uptake, we explored the linear association with
2014/2015 ﬂu vaccine uptake within PCTs as the
dependent variable, and the previous season’s uptake
across PCTs and proportion of vaccine doses adminis-
tered at a pharmacy in 2014/2015 as predictor variables.
To determine the completeness of reporting of ﬂu
vaccine administration in pharmacies in the GP data-
base, we compared the vaccine dose uptake reported by
Sonar 2014/2015 data with the vaccine uptake in loca-
tions other than the GP practice, as reported in
ImmForm 2014/2015 data.
Calculating vaccine delivery costs
We calculated the costs of the ﬂu vaccine delivery
through pharmacies from both the NHS and the phar-
macy perspective and the costs of vaccine delivery
through GPs from the NHS perspective. Investment
costs were annualised by dividing the total costs by the
expected lifetime of the resources. We assumed that ser-
vices for waste disposal and sharps removal from both
pharmacies and GPs were managed and paid for directly
by the NHS. Thus, no additional cost was taken into
account from either the pharmacy or NHS perspective.
Pharmacy vaccine delivery
From the NHS perspective, costs comprise the initial
investment costs of establishing the programme and the
recurrent reimbursement cost to pharmacies, as
reported by NHS LR. The life expectancy of Sonar soft-
ware was assumed to be 5 years. Recurrent costs for
2014/2015 were assumed to be the same as in 2013/
2014. Pharmacies are reimbursed a ﬁxed price by the
NHS for vaccine purchase (£7.08 per dose, including
value-added tax (VAT)) and administration (£7.51 per
dose), irrespective of their choice of vaccine they wish to
offer.
We estimated personnel and material costs from the
pharmacy perspective using data from our pharmacy
survey: the category of personnel working on the ﬂu
vaccine programme, the time spent by personnel on
various tasks, whether any medical supplies are being
used, such as plasters and cotton wool, and whether
they have incurred any capital investment costs to facili-
tate ﬂu vaccine delivery. Gross salaries for pharmacy staff
categories were assigned as follows: assistant—£6.31/h
(minimum wage); technician or dispenser—£6.93/h;8
pre-registration pharmacist—£18 440/year;9 pharmacist
—£45 946 (inﬂated to London salaries from £38 610 by
19%).10
The depreciation time was assumed to be 10 years for
electrical items (ie, refrigerator). We assumed that the
pharmacies paid the list price for their vaccine supply
and calculated this average cost from the list price of the
vaccines11 and the distribution of vaccine brand choice
(see online supplementary information B).
GP vaccine delivery
GPs are reimbursed the list price of the vaccine they
choose to purchase (discounted by a percentage, ie,
determined by the total monthly purchase reimburse-
ment request12), a ﬁxed service payment for vaccine
administration (£7.64 per dose), and a dispensing fee.
The dispensing fee also depends on the monthly
number of doses administered by a clinic and whether
the GP clinic is classiﬁed as a dispensing practice. With
the average number of monthly doses less than 400 per
clinic, we averaged the dispensing practice (230.9p) and
non-dispensing practice (240.6p) reimbursement fees to
get a dispensing fee of £2.25.12 We calculated the cost of
GP ﬂu vaccine delivery per dose as the sum of the cost
of the GP vaccine service fee, the average dispensing fee
and the average cost of vaccine purchase reimbursement
from the NHS. The average cost of vaccine purchase
reimbursement was calculated from the list prices of the
vaccines (British National Formulary (BNF), 2015) and
the distribution of vaccine brand choice by GPs as evalu-
ated in the online survey (see online supplementary
information C).
Implementation of analysis
All analyses were conducted using MATLAB (R2014b.
The MathWorks Inc., Natick, MA; 2014). Code used for
analysis and de-identiﬁed data are available at https://
github.com/katiito/PharmacyVaccination
The survey was administered by NHS LR on behalf of
London School of Hygiene and Tropical Medicine
(LSHTM), and the survey was coded using, and hosted
by, Survey Monkey.
RESULTS
The impact on vaccination uptake
There was no change in reported vaccine coverage
across all risk groups between seasons 2011/2012
(60.1%) and 2012/2013 (60.4%) (t test, p=0.36), or
between 2012/2013 (60.4%) and 2013/2014 (60.5%),
the ﬁrst year of the pan-London pharmacy initiative (t
test, p=0.84; ﬁgure 1A). There was a slight reduction in
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reported vaccine uptake of 1.8–3.0% between 2013/
2014 (60.5%) and 2014/2015 (58.1%; t test, p<0.001),
and of 1.3–3.3% between 2012/2013 and 2014/2015 (t
test, p=0.009; ﬁgure 1A), with the majority of doses
administered to the elderly (ﬁgure 1B).
For 2013/2004, the vaccine uptake ranges between
35% for pregnant women and 70% for those aged
65 years and over (ﬁgure 1). The risk groups that
increased their uptake between the 2012/2003 and
2013/2004 seasons (kidney disease, immunosuppression,
respiratory disease, neurological disease, liver disease,
carers and pregnant women) did so only by 1% or less.
The probability that individuals received their vaccine in
pharmacies varied between 2% (chronic kidney or liver
disease) and 22% for carers (ﬁgure 2A). The probability
that any individual within each group became vaccinated
at a pharmacy stands between 1% for patients with
kidney or liver disease and 8% for carers (ﬁgure 2B).
The fraction of vaccine doses administered at pharma-
cies ranged from 2% to 20% (see online supplementary
ﬁgure S1A). Averaging across all administrative areas,
there was a rise in the fraction of eligible people vacci-
nated at pharmacies, from 3.5% (3.1% to 3.9%) in
2013/2014 to 5.2% (4.8% to 5.6%) in 2014/2015 (see
online supplementary ﬁgures S1B,C, S2). There was a
signiﬁcant increase in the proportion of ﬂu vaccine
doses administered at pharmacies between the ﬁrst and
second year of pan-London pharmacy initiative (t test,
p<0.001, see online supplementary ﬁgure S1A,B). This
increase is explained by both an increase in the number
of participating pharmacies (from 718 in 2013/2014 to
1089 in 2014/2015), as well as a slight increase in the
average number of doses administered at each pharmacy
(95 in 2013/2014, with a total of 68 220 doses and 99 in
2014/2015, with a total of 108 186 doses).
Impact on the reporting system, data collection and
administrative burden
We compared the 2014/2015 Sonar data that record the
number of pharmacy-administered vaccines with 2014/
2015 ImmForm data that record the number of vaccine
doses delivered to GP-registered patients by healthcare
professionals outside the GP practice. This comparison
found that, at most, 75% of pharmacy-administered
vaccine doses are subsequently reported in the
ImmForm data across all PCTs (SD=20%, ﬁgure 3A).
This fraction is an upper bound on the completeness of
reporting because some of the vaccine doses that are
recorded to be administered by a professional outside
the GP practice are not necessarily administered by
pharmacy staff.
Accounting for potential under-reporting in vaccine
coverage and comparing the annual vaccine coverage
before and after the introduction of the pharmacy initia-
tive, we found that there was no change in vaccine cover-
age between years 2011/2012 (60.1%) and 2014/2015
Figure 1 General Practitioner (GP)-reported vaccine uptake by risk group. (A) Vaccine dose allocation across both GPs and
pharmacies as reported in ImmForm reporting system between 2010 and 2014. (B) The fraction of total doses administered per
risk group.
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Figure 2 Pharmacy-reported vaccine uptake by risk group. (A) Probability that vaccine dose was administered at a pharmacy
by risk group. (B) Total vaccine uptake in population at pharmacies across risk groups.
Figure 3 Completeness of reporting across all administrative areas. (A) Maximum estimate of fraction of pharmacy vaccine
doses are subsequently recorded onto general practitioner (GP) recording system. (B) Partitioning 2014/2015 GP data by those
vaccines administered in GPs, those administered in total as reported by GP recording system and those administered
everywhere accounting for under-reporting in GP recording system.
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(59.7%; t test, p=0.34) and a marginal decrease between
years 2012/2013 (60.4%) and 2014/2015 (59.7%; t test,
p=0.05; ﬁgure 3B).
Pharmacy and GP opinions on the pharmacy initiative
Pharmacists reported much greater support for the
pharmacy initiative than did GPs (see online supple-
mentary ﬁgures S3A–C, S4A–F). Responses from the
online survey showed that the vast majority of pharma-
cists thought that the pharmacy initiative eased the
burden on the healthcare system (see online supple-
mentary ﬁgure S3A) and only a minority of pharmacists
were concerned that their lack of access to patient
record data was inefﬁcient or led to difﬁculties with
healthcare provision (see online supplementary ﬁgure
S3B). By contrast, there was an equal split between GPs
as to whether the initiative increased or decreased the
administrative burden on them (29–30%, respectively).
However, 61% of GPs were concerned with a loss of
patient data due to incompleteness of reporting (see
online supplementary ﬁgure S3C). Further comments
by GPs emphasise the issue with incomplete data provi-
sion by pharmacists and the requirement for manual
data entry (see online supplementary information D).
The vast majority of pharmacists believed that their
service improves choice for patients (98%) and is more
convenient for patients (97%). In contrast, GPs are less
uniformly positive about the advantages of pharmacy
vaccination, with 60% believing it improves choice for
patients and 40% believing it is more convenient for
patients. GPs were concerned with a reduced quality of
healthcare provision for their patients (40–50%), issues
with safety (40%) and personal ﬁnancial loss to them-
selves (52%; see online supplementary ﬁgure S3). Most
pharmacists were interested in increasing their vaccine
provision capacity (91%, see online supplementary
ﬁgure S4D). More information from the surveys is
found in online supplementary ﬁgures S3, S4 and sup-
plementary information D).
The impact on individual accessibility to flu vaccine
services
At least 99% of patients receiving the ﬂu vaccine at a
pharmacy were registered with a GP (table 1). For indivi-
duals who received their vaccine at a pharmacy, 24%
(2013/2014) and 20% (2014/2015) did so in a PCT area
where they were not registered with their GP (table 1).
The cost of flu vaccine administration
NHS perspective
We calculated the annual cost per dose to the NHS
(from the commissioner perspective) of pharmacy ﬂu
vaccination delivery to be £14.88 in the 2013/2014
season and £14.78 in the 2014/2015 season (table 2).
The cost per dose decreases a little with the number of
doses delivered due to greater utilisation of the ﬁxed
investment costs. Changing the life expectancy of the
Sonar system from 10 to 2 years, the cost per dose in
2014/2015 varies between £14.75 and £14.89,
respectively.
The annual cost to the NHS of GP ﬂu delivery was
found to be £17.13 per dose (table 2). To calculate the
reimbursed price per dose to the GP, we discounted the
vaccine purchase price by 5.93%, based on a list vaccine
price of £7.70 with on average 340 monthly doses pur-
chased per clinic. If more patients were diverted from
GPs to become vaccinated in pharmacies, the costs of
GP delivery per dose would increase and the costs of
pharmacy delivery per dose would decrease, relative to
the respective investment costs.
Pharmacy perspective
The vast majority of pharmacists reported that they
spend less than half an hour purchasing vaccine stock
for the season, and half of the pharmacists spent less
than 1 h on reimbursement paperwork over the season
(see online supplementary ﬁgure S5A,B). Most of the
vaccine-related pharmacist time is spent with patients,
with a 17 min mean consultation time (see online sup-
plementary ﬁgure S5C). The mean time spent inputting
data and sending patient information to GPs was
reported as 7 min (see online supplementary ﬁgure
S5D).
The cost of the time spent with the patient receiving
the vaccine accounts for 65% of the total cost to the
pharmacist (table 3). The cost of time spent on data
input and GP paperwork accounts for a further 21% of
the total cost to the pharmacist. The average salary cost
of vaccine delivery for a pharmacist is £12.72 per dose
for 2014/2015, with 50% of pharmacists spending
£11.57 per dose or less (table 3 and ﬁgure 4A). The
average list price for the vaccines chosen by the pharma-
cists is £7.37 (ﬁgure 4B, see online supplementary
ﬁgures S5b, S6). Combined, the average pharmacist cost
to deliver a ﬂu vaccine is £20.09 per dose, £5.51 less
Table 1 Total number of reported vaccines administered
in pharmacies from Sonar
2013/2014* 2014/2015*
Pharmacy is in the
same PCT as the
patient’s GP
50 988 (75%) 86 282 (80%)
Pharmacy is in a
different PCT as the
patient’s GP
16 640 (24%) 20 989 (19%)
Patient’s GP is outside
London
3221 3521
Patient’s GP is not
reported (null/unknown/
none)
592 (1%) 915 (1%)
Total vaccine doses
reported
68 220 (100%) 108 186 (100%)
*Per cent of total vaccine doses administered in pharmacy in
parentheses.
GP, general practitioner; PCT, primary care trust.
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than they are reimbursed. Less than 1% of the pharma-
cists reported offering the most expensive vaccine, the
tetravalent preparation (Fluarix Tetra).
DISCUSSION
This study evaluates the costs and beneﬁts of the
pan-London seasonal inﬂuenza programme offering eli-
gible individuals their ﬂu vaccine in community pharma-
cies as an alternative to local GP delivery. To assess ﬂu
vaccine coverage across London before and after the
start of the pharmacy initiative, we analysed two data
sets, ImmForm (GP reports) and Sonar (pharmacy
reports). To evaluate the London-speciﬁc costs from the
NHS and pharmacy perspectives of seasonal ﬂu vaccin-
ation in pharmacies and GPs and the opinions of
vaccine providers, we conducted an online survey admi-
nistered to pharmacists and GPs across London. Our
results do not show any evidence for increased vaccine
uptake as a result of the pan-London ﬂu vaccine
Table 2 NHS perspective costs
Pharmacy delivery GP delivery
Cost per dose Total annual cost Cost per dose Total annual cost*
2013/2014 2014/2015 2013/2014 2014/2015 2013/2014 2014/2015 2013/2014 2014/2015
Recurrent costs
NHS vaccine
service payment
£7.51 £7.51 £512 332 £812 477 £7.64 £7.64 £7 638 296 £7 850 169
Vaccine
purchase
payment†
£7.08 £7.08 £482 998 £765 957 £7.24‡ £7.24§ £7 698 283 £7 911 819
Dispensing fee NA NA NA NA £2.25 £2.25 £2 249 498 £2 311 895
Sonar service
fee
£0.18 £0.12 £12 500 £12 500¶ NA NA NA NA
Investment costs
Sonar
development
£0.11 £0.07 £7200§ £7200¶ NA NA NA NA
Total £14.88 £14.78 £1 015 030 £1 598 134 £17.13 £17.13 £17 456 316 £17 897 611
*Includes all patients 65 and over, carers under 65 years, at risk individuals 16–65 years.
†Includes 20% VAT for each dose reimbursed.
‡Calculated as average vaccine list price with VAT (£7.70) less a discount of 5.93% based on 340 doses per clinic per month.12
§Total cost (£36 000) is depreciated over 5 years.
¶Total cost figures for 2013/2014 used.
GP, general practitioner; NA, not available; NHS, National Health Service.
Table 3 Pharmacy perspective average costs for vaccine administration and purchase
Number of
pharmacies
incurring cost
Cost per year
per pharmacy
if cost incurred
Average pharmacy
cost per season
Average pharmacy
cost per dose‡
2013/2014 2014/2015 2013/2014 2014/2015
Recurrent costs
Plasters 34/58 £1.75 £1.03 £1.03 £0.01 £0.01
Procurement time (excluding brand
choice)
All NA £8.18 £8.18 £0.09 £0.08
Reimbursement paperwork time All NA £121.87 £121.87 £1.28 £1.23
Patient time All NA NA NA £8.11 £8.11
Data input time All NA NA NA £2.66 £2.66
Investment costs
Refrigeration 6/58 £57.00 £5.90 £5.90 £0.06 £0.06
Admin total (with data above) £12.79 £12.72
Admin total (with 1 min data input
time)
£10.61 £10.54
Vaccine purchase list price £7.37 £7.37
Total (with reported data) £20.16 £20.09
*Calculated using a cost of £30,000+ 20% VAT (personal communication NHS LR).
†Base case costs include pharmacist salaries inflated by 19% for London costs.10
‡When per season cost is given, per dose cost calculated by dividing per season cost by 95 (2013/2014) or 99 (2014/2015; average number
of doses delivered by each pharmacists in each season).
NA, not available; VAT, value-added tax.
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pharmacy initiative. The cost to the NHS per vaccine
dose of pharmacy delivery for the London initiative was
lower than that of GP delivery. While we found evidence
that the programme offered convenience and choice to
patients, we found several disadvantages of the pro-
gramme, most notably the incomplete reporting of phar-
macy vaccine delivery into both recording systems.
To calculate incomplete reporting of vaccine delivery
in the GP ImmForm system, we compared the number of
vaccine doses that were noted to be delivered at some-
where other than the GP practice with the number of
doses delivered to patients at pharmacies. If the place of
vaccine dose administration was not correctly registered
in ImmForm, then our results will have underestimated
the number of vaccine doses that are recorded in
ImmForm. Nevertheless, this potential issue further high-
lights the inefﬁcient and information loss-prone nature
of maintaining two recording systems with manual entry.
Moreover, it is unclear how pharmacies ascertain
whether individuals are eligible for vaccination. For a
national programme with increased pharmacy vaccine
uptake to remain efﬁcient, it will be important to easily
identify patient eligibility. For a national system, it may be
helpful to identify advantages and failings of other vac-
cination reporting software, such as the Information
Immunization System (IIS) used in the USA.13
Previous studies suggest that pharmacy-provided vac-
cines may increase uptake of seasonal inﬂuenza vaccine
in high-risk groups. In a survey among 503 high-risk,
non-elderly people in a pilot in Shefﬁeld, 19% of
vaccine recipients at a pharmacy stated that they would
not have received the vaccine otherwise,14 an estimate
consistent with a similar Canadian study.5 In our study, if
19% of people who received the vaccine at a pharmacy,
that is, 19% of 10% of the total eligible population,
would not have done so at their GP, the overall increase
in vaccine coverage would be less than 2%. Such a
change would likely be too small a difference to detect
against the background ﬂuctuations in coverage. We cal-
culated the vaccine coverage for all seasons from
ImmForm data. The true vaccine coverage is likely to be
higher due to evidence of under-reporting of
pharmacy-administered doses in ImmForm data.
However, even accounting for these changes, our results
remain consistent. Nonetheless, our analysis does not
include the possibility of a secular trend of decreasing
vaccine uptake in GP practices, which may obscure
increases in coverage because of pharmacy administra-
tion. Moreover, it is likely that over time,
pharmacy-administered vaccines will become more
widely known and a rise in coverage observed. Our
surveys indicate that pharmacy patients report conveni-
ence as the main factor in the decision to seek the ﬂu
vaccine at a pharmacy rather than their local GP, a
ﬁnding consistent with other studies. For instance,
people trust pharmacists to administer vaccines,4 15 they
are happy with the vaccination service they receive5 14
and they believe that pharmacies offer a convenient way
to receive the vaccine.14 16 Indeed, one study reports
that some people would rather pay out of pocket at the
pharmacy instead of receiving the vaccine for free in
primary care, largely due to convenience and accessibil-
ity.16 In our analysis, we observed a relatively high use of
the pharmacy among carers. This result was also seen in
a pilot programme using community pharmacies on the
Isle of Wight, where there was an increase in uptake
among carers and healthcare workers.17 A higher uptake
among these groups (under 65 years and healthy) was
perhaps expected as in the USA it has been shown that
people who use the out-of-hours service provided by the
community pharmacists (evenings and weekends) mostly
consist of those under 65 years, and those without clin-
ical conditions.3 This result suggests that the group
using pharmacies the most are healthy individuals for
whom vaccination allows only indirect protection of the
elderly or sick. To streamline this route of vaccination, it
may be possible to provide pharmacy vouchers with
carer passports. Conversely, low pharmacy uptake for
risk groups with historically low vaccine uptake, such as
individuals with liver disease, neurological disorders or
immunosuppression, provides increasing inequity for
these groups.
Figure 4 Pharmacy delivery costs. Total administration costs and vaccine purchases prices for pharmacy flu vaccine delivery in
2014/2015 from pharmacy and National Health Service (NHS) perspectives. Pharmacy survey data are only included in
calculation when all cost and time use data are present in order to calculate the total cost for each pharmacy.
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Studies that have previously assessed physician opinion
of regarding non-physician administered vaccine provi-
sion in the USA are broadly consistent with our ﬁndings:
with between 60% and 70% of physicians agreeing that
pharmacists and other providers have adequate training
and provide a more convenient service to the patients.18
Moreover, 70% of physicians report incomplete vaccine
documentation as a result of non-physician vaccine pro-
vision,18 and 90% of physicians have reported that this
incomplete documentation is a barrier to patient
referral.19
Promotion of the pharmacy initiative to eligible
patients was agreed between NHS England and a steer-
ing group from London Pharmaceutical Committee
(LPC). Promotion was predominantly by posters dis-
played in pharmacy windows, most of which were
designed by the LPC, but some pharmacies used general
pharmaceutical company vaccine campaign posters.
Complementary outreach was achieved by other
methods including website promotion (http://www.
myhealthlondon.nhs.uk), twitter, photo shoots (eg,
deputy Mayor of London receiving ﬂu vaccine) and pro-
motion via NHS trust occupational health departments.
Our results suggest that if the reported time use data
in the surveys are accurate and the purchase price of
vaccines is at list price, then London pharmacists would
have needed to recoup £5.51 in order to break even on
ﬂu vaccine provision. There are three reasons how this
shortfall is either recouped or non-existent. First, the
actual time spent administering the vaccine or complet-
ing the data input may be less than reported. For
example, under the assumption that only 1 min per
dose is spent inputting data, the amount needing to be
recouped by pharmacists drops by £2.18–£3.33 (table 3).
As pharmacies adapt to the administration system, the
duration of their patient consultation will likely
decrease. For example, reducing the total time for
vaccine administration and data input by 40% would
allow pharmacies to break even. Moreover, the time
required by pharmacists to administer and complete
data entry per dose seems high relative to ﬂu vaccina-
tions in clinics,20 suggesting that bottom-up costing is
likely to overestimate the costs of vaccine delivery.
Overestimation of time spent administering vaccination
or recording administration may arise due to the percep-
tion among pharmacists that our survey may inﬂuence
remuneration decisions. Second, in practice, pharmacists
will likely not pay the list price of their chosen vaccine,
instead negotiating directly with the manufacturers for
the best deal. For instance, if pharmacists wanted to min-
imise their expenditure based solely on the list price,
they would choose Inﬂuvac (Abbott) retailing at £5.22
per dose, leaving a proﬁt after reimbursement of £0.68.
Thus, as many other brands were chosen, the negotiated
price for pharmacy stock must provide more than a
£0.68 per dose advantage. Third, pharmacists will hope
to generate income by the increased footfall in their
pharmacy. Even if the total cost is not recouped, the
pharmacy may be willing to pay for the beneﬁt of devel-
oping stronger patient conﬁdence in their healthcare
provision. We did not attribute any additional recurrent
or investment costs of the GP delivery programme above
the ﬂu vaccine service fee and the purchase reimburse-
ment price. Hence, the costs of the GP programme is
likely underestimated as we did not include the costs of
any ﬂu communication material provided to GPs and
the costs of managing vaccine data supplied by GPs.
However, the cost of the pharmacy option may also be
underestimated as it does not include additional costs
for GP practices to input data from pharmacists, or
contact patients who have already received the vaccine
but are not recorded on the system. This latter cost may
be relatively high due to the level of under-reporting of
pharmacy uptake on the GP ImmForm system. The
majority of vaccine doses in GP practices are adminis-
tered by nurses or healthcare assistants, and as the salary
of a nurse in a GP practice is only two-thirds of a
pharmacist10 and even less for a healthcare assistant,
and most of the vaccine delivery cost results from health-
care staff time, one would expect personnel costs for
GP-based vaccine administration to be less costly than
those for pharmacy-based vaccine administration.
Many GPs currently offer a call reminder service for
the 65 years and over and a call and recall reminder
service for other risk groups. If the costs for this
reminder service are recouped in the service fee reim-
bursed to GPs per patient vaccinated, then decreasing
the number of reimbursed service fees but maintaining
the full call service for all eligible patients increases GP
practice costs per vaccine dose. As GPs are paid for the
vaccination coverage they achieve (irrespective of
whether the practice delivered the vaccines themselves)
under the Quality and Outcomes Framework (QOF),
GP practices have an incentive to report complete
uptake ﬁgures via ImmForm. However, there is no
similar incentive to ensure complete reporting of
pharmacy-delivered vaccine doses to GP practices.
Moving to a single recording database system that is
accessible to both pharmacists and GPs would align the
incentives of recording by pharmacies for reimburse-
ment with recording for complete patient health
records. In the London pharmacy initiative, GPs and
pharmacists received vaccine purchase reimbursement
from the NHS differently; while GPs receive the list
price for whatever vaccine stock they use, pharmacists
receive a ﬁxed fee regardless of the brand chosen. This
reimbursement structure provides different incentives
for vaccine brand choice. Leaving aside the
health-related preferences of the healthcare provider,
GPs would ﬁnancially beneﬁt from achieving a differ-
ence between the list vaccine price and the negotiated
vaccine price. Pharmacists would also beneﬁt from a
large difference between the list vaccine price and the
negotiated vaccine price, but any proﬁt they receive
would ultimately be contingent on the negotiated price
to reimbursement fee difference. Therefore, with a ﬁxed
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fee reimbursement contract, pharmacists will have less
incentive to offer the more expensive quadrivalent
vaccine (Fluarix Tetra). Indeed, across London, <1% of
pharmacists offered the Fluarix Tetra compared with
5.5% of GPs. Previous proposals by the Department of
Health have sought to procure ﬂu vaccines centrally to
streamline the vaccine programme and reduce vaccine
purchase costs have been met with resistance by GPs.21
The current national pharmacy programme is equally
unpopular with GPs,6 who are concerned with loss of
income. Commissioning any re-evaluated vaccine pro-
gramme is subject to various trade-offs: most notably
maintaining incentives for vaccine provision, keeping
vaccine purchase and reimbursement costs low, and
ensuring high quality and complete reporting. Further,
it is possible that there will be emerging issues when
scaling up the pharmacy programme to a national level:
more premises offering ﬂu vaccines—such that the
number of doses offered per premises decreases,
coupled with the potentially opportunistic nature of
pharmacy vaccination will likely result in more wasted
ﬂu doses per box compared with a limited number of
providers, with a stable number of patients.
The ‘Community Pharmacy Seasonal Inﬂuenza
Vaccination Advanced Service’, allowing pharmacies to
administer ﬂu vaccines, has been introduced in
autumn/winter 2015.22 The programme differs from the
pan-London initiative in a number of key ways: ﬁrst,
pharmacists are reimbursed for vaccine purchase in the
same way as GPs, such that they claim for the list price
(plus VAT) of the vaccine they choose to administer;
second, they receive the same service payment as GPs of
£7.64 per dose; third, pharmacists are paid an additional
£1.50 per dose to cover training, revalidation and waste
disposal.23
This study is subject to several limitations that must be
considered before generalising the results countrywide.
First, the coverage and survey data were London-speciﬁc,
and these may not be representative of the country.
Second, the survey response rate was very low, particu-
larly for pharmacists. Such a low response may be indica-
tive of a biased sample, and more importantly, not
provide a large enough sample size for precise estimates
of costs, which are calculated from self-reported activity
durations. To achieve more accurate estimates of costs
from all perspectives, it may be beneﬁcial to conduct a
larger, nationwide time use survey. Third, survey
responses and coverage data are from 1 or 2 years,
respectively. While more data may provide a more
precise estimate of outcomes, it is also worth noting that
a longer period of pharmacy-based vaccine delivery may
increase the awareness of such a programme, and there-
fore ultimately vaccine coverage may increase over time.
Furthermore, the analysis did not account for any under-
lying secular trends in the uptake of ﬂu vaccination that
may obscure any increase due to the pharmacy initiative.
Fourth, the survey did not question patients and, not-
withstanding the previous patient survey in London,
there may be some interesting aspects of pharmacy deliv-
ery that have not been reported. For example, our GP
survey found that GPs were concerned about the loss of
healthcare opportunity for their patients, but given that
nurses are more likely to administer ﬂu vaccines in GP
surgeries, and that pharmacists were probably more
likely to have more time to administer the jabs, this may
be a concern not echoed for patients. Finally, surveys
were carried out retrospectively, and thus pharmacists
may be prone to misreport activity durations on time use
surveys. A more accurate survey would be conducted
through the vaccination season in real time.
In summary, our ﬁndings indicate that the total cost
per dose of seasonal ﬂu vaccination is slightly lower
when it is administered by pharmacies compared with
GPs. However, we found no evidence of increased
vaccine coverage as a result of the pharmacy initiative.
Further, our results suggest that maintaining two report-
ing systems for GPs and pharmacies leads to substantial
under-reporting of vaccine uptake and unreliable GP
vaccine uptake data.
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